US 20040038307A1
· Lee et al.
· 2004
[cited by applicant]
US 20080108070A1
· Xu et al.
· 2008
[cited by applicant]
US 20110262348A1
· Movahedi et al.
· 2011
[cited by applicant]
US 20140242077A1
· Choi et al.
· 2014
[cited by applicant]
US 20150190506A1
· Cheung et al.
· 2015
[cited by applicant]
US 20150266958A1
· Hermans et al.
· 2015
[cited by applicant]
US 20170290913A1
· Cheung et al.
· 2017
[cited by applicant]
JP 2009504191A
· 2009
[cited by applicant]
JP 2013539364A
· 2013
[cited by applicant]
RU 2013110576A
· 2014
[cited by applicant]
WO 2007024715A2
· 2007
[cited by applicant]
WO 2010007376A2
· 2010
[cited by applicant]
WO 2010077634A1
· 2010
[cited by applicant]
WO 2012027570A2
· 2012
[cited by applicant]
WO 2012032433A1
· 2012
[cited by applicant]
WO 2014022758A1
· 2014
[cited by applicant]
WO 2014028776A1
· 2014
[cited by applicant]
WO 2014100079A1
· 2014
[cited by applicant]
WO 2014209804A1
· 2014
[cited by applicant]
WO 2015095412A1
· 2015
[cited by applicant]
WO 2016149201A2
· 2016
[cited by applicant]
WO 2018115003A2
· 2018
[cited by applicant]
Bartkowiak et al., “4-1BB agonists: Multi-potent potentiators of tumor immunity,” Frontiers in Oncology, vol. 5, No. 117, pp. 1-16 (2015).
[cited by applicant]
Borisov et al., “Tumor microenvironment as a target of malignant gliomas treatment” Malignant Tumours; vol. 4:14-23 (2015).
[cited by applicant]
Cardoso et al., “Single-Domain Antibodies Targeting Neuraminidase Protect against an H5N1 Influenza Virus Challenge,” Journal of Virology; vol. 88, No. 15; pp. 8278-8296 (2014).
[cited by applicant]
Chang et. al., “The Development of Bispecific Hexavalent Antibodies as a Novel Class of Dock-and-LockTM (DNLTM) Complexes,” Antibodies., vol. 2, No. 2; pp. 353-370 (2013).
[cited by applicant]
Chen et al., “Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model,” Cancer Immunology research. vol. 3, No. 2; pp. 149-160 (2014).
[cited by applicant]
Chen et al., “Fusion protein linkers: property, design and functionality,” Advanced drug delivery reviews, vol. 65, No. 10, p. 1357-1365 (2013).
[cited by applicant]
Colman et al., “Effects of amino acid sequence changes on antibody-antigen interactions, Research in Immunology,” vol. 145, No. 1, p. 33-36 (1994).
[cited by applicant]
Cuesta et al., “Multivalent antibodies: when design surpasses evolution,” Cell Press Trends in Biotechnology (28), pp. 355-362 (2010).
[cited by applicant]
Dondelinger et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition.” Frontiers in Immunology, vol. 9, pp. 1-15 (2018).
[cited by applicant]
Extended European Search Report dated Aug. 19, 2019 for International Application No. PCT/US2017/013040; 7 pages.
[cited by applicant]
Fisicaro et al., “Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV,” Gastroenterology, vol. 143, No. 6, pp. 1576-1585 (2012).
[cited by applicant]
Gilboa et al., “Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors,” Clin. Cancer Res. vol. 19, No. 5, pp. 1054-1062 (2013).
[cited by applicant]
He et al., “Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies,” Oncotarget, vol. 8: 67129-67139 (2017).
[cited by applicant]
Holt et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, vol. 21: 484-490 (2003).
[cited by applicant]
Huang et al., Human B Cells Accumulate immunoglobulin V Gene Somatic Mutations in a Cell Contact-Dependent Manner in Cultures Supported by Activated T cells But Not in Cultures Supported by CD40 Ligand. Clinical and Exp…
[cited by applicant]
Iezzi et al., “Promise of Modular Targeting in Cancer Imaging and Treatment,” Frontiers in Immunology, vol. 9: 1-11, 11 pages (2018).
[cited by applicant]
Inman et al., “Utomilumab/Pembrolizumab Combo Shows responses in Different Solid Tumors”, XP002793239, Retrieved from the Internet: URL:https://www.targetedonc.com/conference/asco-immune-2016/utomiluma/pembrolizumab; 2 …
[cited by applicant]
International Search Report and Written Opinion for International Application PCT/US17/13040 dated Jul. 20, 2017; 8 pages.
[cited by applicant]
Kontermann et al., “Bispecific antibodies”, Drug Discovery Today, vol. 7, No. 20, p. 838-847 (2015).
[cited by applicant]
Linch et al., “OX40 agonists and combination immunotherapy: putting the pedal to the metal,” Frontiers in Oncology, vol. 5, pp. 34:1-14 (2015).
[cited by applicant]
Locksley et al., “The TNF and TNF receptor superfamilies: integrating mammalian biology,” Cell, vol. 104, No. 4, p. 487-501 (2001).
[cited by applicant]
Lu et al. “Structure of FcyRI in Complex with Fc Reveals the Importance of Glycan Recognition for High-Affinity IgG Binding,” Proceedings to the National Academy of Sciences of USA. vol. 112, No. 3; pp. 833-838; p. 834,…
[cited by applicant]
Maeda et al., “Engineering of functional chimeric protein G-Vargula Luciferase,” Analytical biochemistry, vol. 249, No. 2, p. 147-152 (1997).
[cited by applicant]
Nelson et al., “The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment,” J. Immunol. Res., N.789069, pp. 1-14 (2014).
[cited by applicant]
Pakula et al., “Genetic analysis of protein stability and function,” Annual Review of Genetics, V. 23, pp. 289-310 (1989).
[cited by applicant]
Pardon et al., “A general protocol for the generation of Nanobodies for structural biology,” Nature Protocols (9)(3), pp. 674-693 (2014).
[cited by applicant]
Raaphorst et al. Restricted Utilization of Germ-line VH3 genes and Short Diverse Third Complementarity-Determining Regions (CDR3) in Human Fetal B Lymphocyte Immunoglobulin Heavy Chain Rearrangements. European Journal o…
[cited by applicant]
Rahbarizadeh et al., “Nanobody; an Old Concept and New Vehicle for Immunotargeting,” Immunological Investigations, Informa Healthcare USA, Inc. vol. 40, No. 3, pp. 299-338, (2011).
[cited by applicant]
Rahbarizadeh et al., “Nanobody, New Agent for Combating Against Breast Cancer Cells”, Breast Cancer—Current and Alternative Therapeutic Modalities, pp. 347-370 (2011).
[cited by applicant]
Rossi et al., “The Dock-and-Lock Method Combines Recombinant Engineering with Site-Specific Covalent Conjugation to Generate Multifunctional Structures,” American Chemical Society. p. 309-323 (2011).
[cited by applicant]
Safdari et al., “Antibody humanization methods—a review and update,” Biotechnology and Genetic Engineering Reviews, vol. 29, No. 2, p. 175-186 (2013).
[cited by applicant]
Sanmamed et al., “Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rynull Immunodeficient Mice”, Cancer Research, (75)(17), pp. 3466-3478 (2015).
[cited by applicant]
Scott et al., “Antibody therapy of cancer,” Nat Rev. vol. 12: 278-287 (2012).
[cited by applicant]
Search Report issued in corresponding Singaporean Application No. 11201805532X, dated Aug. 30, 3019, 5 pages.
[cited by applicant]
Shen et al., “Single variable domain-IgG fusion: a novel recombinant approach to Fc domain-containing bispecific antibodies,” Journal of Biological Chemistry, vol. 281, No. 16, pp. 10706-10714 (2006).
[cited by applicant]
Teplyakov et al., “Antibody modeling assessment II Structures and models,” Proteins: Structure, Function, and Bioinformatics, vol. 82, No. 8, p. 1563-1582 (2014).
[cited by applicant]
Torres M. et al., “The immunoglobulin constant region contributes to affinity and specificity,” Trends in immunology, vol. 29, No. 2, p. 91-97, pp. 93-94 (2008).
[cited by applicant]
Tran et al., Production of Anti-cancer Immunotoxins in Algae: Ribosome Inactivating Proteins as Fusion Partners. Biotechnology and Bioengineering, vol. 110, No. 11; pp. 1-32 (2013).
[cited by applicant]
Williams et al., “The Human Neonatal B Cell Response to Respiratory Syncytial Virus uses a Biased Antibody Variable Gene Repertoire that Lacks Somatic Mutations” Molecular Immunology. vol. 47, No. 2-3; pp. 1-21; p. 5 (2…
[cited by applicant]
Zhang et al., “Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade,” Cell Disco. vol. 3: 1-12, (2017).
[cited by applicant]